Aradigm to Present at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2016 on February 8
HAYWARD, Calif.--(BUSINESS WIRE)--
Aradigm Corporation (Nasdaq:ARDM) (the "Company") today announced that
President and Chief Executive Officer, Igor Gonda, Ph.D., will present
at the 18th Annual BIO CEO & Investor Conference 2016 on
Monday, February 8, 2016, at 10:30 a.m. ET. The event will be held at
the Waldorf-Astoria Hotel in New York, New York.
Interested parties can access a live audio webcast and slide
presentation at www.aradigm.com.
An archived presentation will be available on the Company's Web site for
Aradigm is an emerging specialty pharmaceutical company focused on the
development and commercialization of drugs for the prevention and
treatment of severe respiratory diseases. Aradigm is currently in Phase
3 development of Pulmaquin (an investigational proprietary formulation
of ciprofloxacin for inhalation) for the treatment of non-cystic
fibrosis bronchiectasis. Aradigm's inhaled ciprofloxacin formulations
are also product candidates for treatment of patients with cystic
fibrosis and non-tuberculous mycobacteria, and for the prevention and
treatment of high threat and bioterrorism infections, such as inhaled
tularemia, pneumonic plague, melioidosis, Q fever and inhaled anthrax.
In addition, Aradigm has a pipeline composed of programs to prevent
diseases in tobacco smokers through smoking cessation and a diagnostic
program to detect aspirations of gastrointestinal fluid into the
More information about Aradigm can be found at www.aradigm.com.
Aradigm and the Aradigm Logo are registered trademarks of Aradigm
View source version on businesswire.com: http://www.businesswire.com/news/home/20160202005062/en/
Nancy Pecota, 510-265-8800
Source: Aradigm Corporation
News Provided by Acquire Media